Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Exelixis’ Cabometyx approved in second-line liver cancer in US

pharmaphorumJanuary 16, 2019

Tag: Liver cancer , clinical development , Exelixis , Cabometyx

PharmaSources Customer Service